Chair: Dr David Pinato
Clinical Senior Lecturer and Consultant Medical Oncologist, Chief Investigator of the OnCovid Study, Imperial College London
Effective management of adverse events is critical for both patients’ outcome and their quality of life. This webinar seeks to provide a tumour agnostic educational tool on the effective management of adverse events with immunotherapy combinations.
This meeting is fully funded by Eisai and is non-promotional. Content and speakers were chosen by the company. The meeting is intended for healthcare professionals only.
Date of preparation: July2021 UK-ONC-21-00065
During this session, participants will be able to:
This webinar is available for on-demand viewing. The webinar recording will be available for registered delegates up to 30 days after the live webinar broadcast via Zoom. The link will be sent 24 hours after the webinar takes place.
Join in the conversation online #RSMLive
Follow us on Twitter: @RoySocMed
Clinical Senior Lecturer and Consultant Medical Oncologist, Chief Investigator of the OnCovid Study, Imperial College London
Consultant Medical Oncologist University L'Aquila, Italy and Imperial College Hospital, London, Visiting Reseracher Imperial College Hospital London
Medical Oncology Registrar, Clatterbridge Cancer Centre
Dr Anna Olsson-Brown graduated with a BSc (Hons) in Pharmacology, before training in Medicine at the University of Liverpool. She is currently a Medical Oncologist at the Clatterbridge Cancer Centre, Liverpool and a previous MRC Clinical Research Fellow at the University of Liverpool.
Dr Olsson-Brown is also the Chair of the Academy of Trainee Doctor Group at the Academy of Medical Royal Colleges and the recent past-Chair of the National Oncology Trainees Collaborative for Healthcare Research (NOTCH). Her clinical interests include the use and toxicities of cancer immunotherapies, and her research is based on understanding the immunological events that occur in the presence of immunotherapy that lead to toxicity. She has established a regional pan-tumour immunotherapy service that supports patients on immunotherapy and those experiencing toxicity and clinically manages patients with toxicity as well as those with melanoma and sarcoma.
Chair: Dr David Pinato, Clinical Senior Lecturer and Consultant Medical Oncologist, Chief Investigator of the OnCovid Study, Imperial College London
Chair: Dr David Pinato and then Expert Panel with Dr Alessio Cortellini and Dr Anna Olson-Brown
Dr Alessio Cortellini, Consultant Medical Oncologist University L'Aquila, Italy and Imperial College Hospital, London, Visiting Researcher Imperial College Hospital London
Dr Anna Olsson Brown, Medical Oncology Registrar, Clatterbridge Cancer Centre
Chair: Dr David Pinato
Online
This meeting is fully funded by Eisai and is non-promotional. Content and speakers were chosen by the company. The meeting is intended for healthcare professionals only.
Date of preparation: July2021 UK-ONC-21-00065
Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM nor the speaker's organisations.
Special rates for difficult times
The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s weekly COVID-19 Series webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic.